All companies.webp)
Visit website
Global Cancer Technology
OperatingGlobal Cancer Technology, Inc.
Founded 2017
GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.
Post-money valuation ⓘ
$26.7M
As of Apr 2022 · from Global Cancer Technology Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$107,000
Across 3 rounds since 2019
Latest share price
$2.00
Global Cancer Technology Common Stock 2 offering price
Financials
FY2017–FY2020 · from SEC filings · hover any figure for its source$25K
−$347K
2017
$0
−$359K
2018
$0
−$674K
2019
$0
−$739K
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2017
FY2018
FY2019
FY2020
Income statement
Revenue
$25,000
$0
$0
$0
Cost of goods sold
$10,000
$0
$0
$0
Gross margin
60%
—
—
—
Net income
-$347,218
-$359,128
-$674,005
-$739,118
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$24,850
$6,104
$1,071
$49,137
Accounts receivable
$0
$0
$0
$0
Total assets
$35,898
$7,151
$251,420
$51,964
Short-term debt
$75,000
$242,500
$0
$0
Long-term debt
$0
$0
$0
$0
Total liabilities
$322,677
$242,500
$383,035
$0
Other
Headcount
1
0
1
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$26.7M
post-money
Global Cancer Technology Common Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.1MPost-money $26.7M
Raised $0 / $7M
Raised $107K / $107K
Reg CF annual-report compliance
Possibly delinquent
Filed 1 of 7 annual reports (FY2019–FY2025)
Missing: 2019, 2021, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 22 filings on EDGARSource: ManualCIK 0001743261Share price $2.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.